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ABSTRACT
MODESTI, P. A., S. RAPI, R. PANICCIA, G. BILO, M. REVERA, P. AGOSTONI, A. PIPERNO, G. E. CAMBI, A. ROGOLINO,
A. BIGGERI, G. MANCIA, G. F. GENSINI, R. ABBATE, and G. PARATI. Index Measured at an Intermediate Altitude to Predict
Impending Acute Mountain Sickness. Med. Sci. Sports Exerc., Vol. 43, No. 10, pp. 1811–1818, 2011. Purpose: Acute mountain
sickness (AMS) is a neurological disorder that may be unpredictably experienced by subjects ascending at a high altitude. The aim of
the present study was to develop a predictive index, measured at an intermediate altitude, to predict the onset of AMS at a higher
altitude. Methods: In the first part, 47 subjects were investigated and blood withdrawals were performed before ascent, at an
intermediate altitude (3440 m), and after acute and chronic exposition to high altitude (Mount Everest Base Camp, 5400 m (MEBC1
and MEBC2)). Parameters independently associated to the Lake Louise scoring (LLS) system, including the self-reported and the
clinical sections, and coefficients estimated from the model obtained through stepwise regression analysis were used to create a predictive
index. The possibility of the index, measured after an overnight stay at intermediate altitude (Gnifetti hut, 3647m), to predict AMS (defined as
headache and LLS Q 4) at final altitude (Capanna Margherita, 4559m), was then investigated in a prospective study performed on 44 subjects
in the Italian Alps. Results: During the expedition to MEBC, oxygen saturation, hematocrit, day of expedition, and maximum velocity of
clot formation were selected as independently associated with LLS and were included in the predictive index. In the Italian Alps, subjects
with a predictive index value Q 5.92 at an intermediate altitude had an odds ratio of 8.1 (95% confidence limits = 1.7–38.6, sensitivity = 85%,
specificity = 59%) for developing AMS within 48 h of reaching high altitude. Conclusion: In conclusion, a predictive index combining
clinical and hematological parameters measured at an intermediate step on the way to the top may provide information on impending AMS.
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N
owadays, owing to the modern tourist industry, ac-
cess to high altitudes is made easy. Within 6–12 h
after arrival at altitudes greater than 2500 m and
consequent acute exposition to hypobaric hypoxia, nonaccli-
matized mountaineers may experience nonspecific symp-
toms including headache, nausea, anorexia, insomnia, fatigue/
lassitude, vomiting, and dizziness (14). When these symptoms
are assessed and rated in severity on a scale of 1–3 with the
generally accepted Lake Louise scoring (LLS) system (22),
the presence of acute mountain sickness (AMS) can be clin-
ically diagnosed at the presence of a headache and at least
one of the other symptoms.
Although not generally life-threatening, AMS is a clinical
and pathophysiological continuum with high-altitude cere-
bral edema (14,25), a potentially fatal condition marked by
the onset of ataxia and altered consciousness (2,14). As very
few medications for AMS treatment are available, subjects
with AMS should descend or be evacuated when LLS does
not abate or worsen at any point within 24–48 h (25). At
high altitude, this decision may, however, be hindered by
accessibility of the hut, the geographic layout, and mostly by
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weather conditions. In addition, evacuation can sometimes
be severely delayed among the local staff engaged in the
expedition, who may deny AMS symptoms because they
worry about losing their jobs (7). Therefore, a great interest
exists regarding the possibility to screen subjects who may
undergo a life threat (25).
Rate of ascent, heavy exercise, and individual suscepti-
bility are the recognized important determinants for the
onset of AMS (24). Individual susceptibility, however, can
only be ascertained after a first episode (25), and although
a relationship between oxygen saturation (SaO2) and the
subsequent development of AMS (9) was observed, at pres-
ent there is no way to predict AMS (24). Mild to moderate
AMS was found to be associated with different pathophys-
iological changes, including relative hypoventilation (20),
impaired gas exchange (interstitial pulmonary edema) (13),
fluid retention and redistribution (27), and increased sym-
pathetic drive (5). Studies performed on mountaineers after
a rapid ascent by foot to high altitude in the Alps (94000 m)
revealed that AMS with a score Q 4 was also associated with
mild but significant shortening of activated partial throm-
boplastin time in the absence of any evidence of throm-
bin generation or fibrin formation (3); no blood coagulation
changes were observed in mountaineers not reaching the
same AMS score (4).
The complexity and the dynamic nature of AMS might
represent significant obstacles toward the identification of
a single parameter for predicting the disease. Therefore, the
aim of the present study was to develop for the first time
a predictive index, combining simple clinical and hemato-
logical parameters (i.e., hematocrit, oxygen saturation, etc.),
which may be used at intermediate altitude to predict the onset
of AMS at high altitude. A two-phase study was thus de-
signed: in the first phase, we analyzed data collected within
the frame of the HIGH altitude CArdiovascular REsearch
(HIGHCARE) project at Mount Everest Base Camp (MEBC,
5400 m) to estimate the parameters to be included in the
equation for deriving the clinical prediction index; in the sec-
ond phase, an expedition to Monte Rosa (Italian Alps) was
set up to validate the clinical prediction model by using data
obtained after an overnight stay at the Gnifetti hut (3647 m)
to predict an onset of AMS at the final high-altitude destina-
tion (Capanna Margherita (CM) hut, 4559 m).
MATERIALS AND METHODS
High-altitude ascent technique and laboratory
setting. All volunteers were all in good general health and
were all living permanently at G500 m above sea level.
Exclusion criteria included subjects with known cardiovas-
cular disease, chronic cardiovascular therapy, repeated pro-
longed exposures to altitudes 9 3000 m in the 8 months
preceding the expeditions, history of severe mountain sick-
ness, history of angioedema, and pregnancy. Professional
athletes were not included in the study. All subjects under-
went a general safety medical checkup and baseline testing
at the S. Luca Hospital in Milan (Italy) (baseline test). Both
projects were approved by the ethical committee of the
University of Milan Bicocca, and all subjects gave written
informed consent to participate.
The first phase of the study was performed within the
frame of the HIGHCARE project (2008), which included a
total of 47 subjects (32 males and 15 females) age 24–62 yr
(40 T 9 yr). The expedition traveled from Kathmandu
(1200 m) to Lukla (2800 m) by plane and on the same day
by helicopter to Namche Bazaar (Namche, 3440 m), where
we stopped off for measurements (September 14 and 15).
Then, after a 2-d hike, we reached Periche (4200 m) where
we stopped off again for 1 d for further acclimatization.
Then finally after a further 2-d hike, we reached our desti-
nation (MEBC, 5400 m) where tests were carried out in a
heated tent after acute (September 23–25, MEBC1) and
prolonged exposure to high-altitude hypoxia (October 2
and 3; MEBC2; Fig. 1A). During the four evaluation ses-
sions (sea level, exposure to intermediate altitude, acute
and prolonged exposure to high altitude), all subjects under-
went clinical evaluation with LLS assessment (22), transcu-
taneous hemoglobin oxygen saturation (pulse oximeter, Life
FIGURE 1—Altitude ascent profile of the expeditions to Mount Everest Base Camp (A) and CM (Monte Rosa) (B). Data collection points are indicated
with arrows.
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Scope I; Nihon Kohden, Tokyo, Japan), and blood pressure
(OMRON M5-I; Omron, Tokyo, Japan) measurements, and
blood withdrawal.
The expedition to the CM hut, located on top of one of
Monte Rosa’s peaks, in the Swiss-Italian Alps, at an altitude
of 4559 m, included a group of 44 subjects (23 males and
21 females) age 25–59 yr (36 T 9 yr), 17 among them
had also taken part in the HIGHCARE project. Two years
elapsed between the Mount Everest Base Camp expedition
and the trek to the CM, so there was sufficient washout
between altitude exposures. Subjects traveled by car from
Milan to Alagna Valsesia (1130 m), ascended by cable car
up to Punta Indren (3200 m) and then reached by foot the
Gnifetti hut (3647 m). After an overnight stay at the Gnifetti
hut, all subjects underwent LLS assessment, pulse oximetry
measurement, and blood withdrawal. Then, subjects hiked to
CM, where LLS assessment was carried out 24 and 48 h after
arrival (Fig. 1B).
AMS scoring system. To assess the degree of AMS,
we used the self-reported and the clinical sections of the
Lake Louise AMS scoring system (22). The AMS self-report
is the sum of answers to five questions (headache, gastro-
intestinal symptoms, dizziness, lassitude or fatigue, sleeping
difficulty), each one rating from 0 to 3. The clinical assess-
ment score was given through the examination of three signs
by the physician: mental status rating from 0 to 4, ataxia
rating from 0 to 4, and peripheral edema rating from 0 to 2.
The result of the clinical assessment score was added to the
AMS self-report score. In our study, we defined AMS at
the presence of headache with LLS Q 4. At CM, the highest
LLS score recorded in the presence of headache was used
to AMS. Subjects with AMS at the Gnifetti hut were not
used in the evaluation of the predictive index.
Collection of blood samples. Venous blood samples
for thromboelastometry (2.5 mL) were collected early morn-
ing, after overnight fasting, into a tube containing trisodium
citrate 0.129 M at a proportion of 1:9 (anticoagulant–blood),
and tests were started within 15 min after venipuncture.
Hematocrit was immediately assessed by ABL77 (Radiome-
ter Copenhagen, Bronshoj, Denmark). Venous blood samples
for epinephrine (E) and norepinephrine (NE) assay (5 mL)
were centrifuged, and the isolated plasma samples were snap-
frozen and stored in liquid nitrogen until assay. NE and E
levels were then assayed through high-performance liquid
chromatography with electrochemical detection (21).
Thromboelastometry measurements. Intrinsic acti-
vation of hemostasis (INTEM assay) was triggered through
cephalin (ellagic acid) in the four-channel ROTEM device
according to protocols and with type and concentration of
reagents as provided by the manufacturer. Investigated
parameters were the following: clotting time (CT), the time in
seconds from the beginning of the coagulation analysis until
an increase in amplitude of 2 mm; clot formation time (CFT),
the time in seconds between an increase in amplitude of the
thromboelastogram from 2 to 20 mm; maximum clot firmness
(MCF), the maximal amplitude (mm) of the tracing reached
in thromboelastogram; maximum velocity (MAXV), defined
as the peak of the first derivative of the thromboelastographic
clotting curve as expressed in millimeters per minute; alpha
(>) angle, the tangent to the clotting curve through the 2-mm
point (18). Intra-assay variation (based on four simultaneous
measurements of two healthy male subjects) was 4% for
CT, 10% for CFT, 4% for > angle, 4% for MCF, and 8%
for MAXV. A preliminary test of instruments and experi-
mental procedures was performed at simulated high altitude
(21,000 ft, 6400 m) in the hypobaric chamber of the ‘‘Centro
Sperimentale di Volo’’ (Air Force of Italy, Pratica di Mare,
Rome, Italy). The exact same instruments were used in both
expeditions.
Statistical analysis. Data collected in the HIGHCARE
expedition are expressed as mean T SD values or confi-
dence limits (CL) at 95% for continuous variables. Cate-
gorical variables are presented as counts and percentages.
Comparisons were made through ANOVA tests followed by
post hoc ANOVA with Bonferroni test for multiple com-
parisons. Categorical variables were compared with Fisher’s
exact test.
Time patterns of variables measured in the subjects who
did and did not experience AMS during the HIGHCARE
expedition were compared using a linear mixed-effect model
(group  time interaction fitted through the restricted max-
imum likelihood) (11). Variables independently associated
with LLS were then selected through the stepwise multi-
ple linear regression analysis (12), including data collected
during all four steps of the HIGHCARE expedition (base-
line, Namche, MEBC1, and MEBC2). In particular, age,
gender, hematocrit, body mass index, systolic and diastolic
blood pressure (BP), HR, breathing rate, day of expedition,
barometric pressure, pulmonary artery pressure, oxygen satu-
ration, catecholamine plasma concentration, and coagulation
parameters were included as independent variables with LLS
included as dependent variable. P G 0.05 was considered
significant to stay into the final model. The regression coef-
ficients with their 95% CL are presented with the P value
of the t-test against 0.
The coefficients estimated from the model are the weight
of each parameter. Therefore, each parameter was multiplied
by its coefficient, and the results were summed to form a
final combined value. The value was then expressed as the
reciprocal multiplied by 100 so that a higher index may
indicate a higher risk of developing AMS. Values measured
at intermediate altitude (Namche) were then used to calcu-
late the predictive index of each subject. Receiver operating
characteristic (ROC) curve analysis was used to calculate
the cutoff value and the sensitivity and specificity of the
predictive index measured in Namche to predict AMS
at MEBC1. A prospective study in the Italian Alps was then
performed to avoid the bias of using the same classified
observations used to estimate the parameters of the
model (19).
In the second phase, the capability of the index measured
at intermediate altitude (Gnifetti hut) to identify subjects
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with impending AMS at final altitude (CM) was then
expressed as odds ratio (OR, calculated as the ratio of the
odds of AMS occurring in the groups with index value be-
low and over cutoff value). The following parameters of test
performance were also calculated: positive predictive value
(the proportion of patients with positive test results who had
AMS at final altitude), negative predictive value (the pro-
portion of patients with negative test results who had AMS
at final altitude), sensitivity (the true positive tests per total
affected patients tested), and specificity (the true negative
tests per unaffected patients tested).
Data were analyzed using the Statistical Package for the
Social Sciences (SPSS v17; SPSS, Inc., Chicago, IL).
RESULTS
Clinical findings and environmental variables
during the HIGHCARE expedition. Mean atmospheric
pressure and oxygen air pressure at the different step of
HIGHCARE are reported in Table 1. Systolic and diastolic
blood pressure significantly increased during the ascent,
whereas O2 saturation decreased (Table 1). At Namche, 24
TABLE 1. Variables measured at baseline, at Namche Bazaar (Namche), and Mount Everest Base Camp (MEBC1 and MEBC2) in the whole group (n = 47) and in subjects who experienced
(AMS, n = 16) and who did not experience (No AMS, n = 31) acute mountain sickness (headache with LLS Q 4).
ANOVA Mixed Model Gr  t
Variables Baseline (Sea Level) Namche (3300 m) MEBC1 (5400 m) MEBC2 (5400 m) F P P
Air pressure (mbar) 1016 679 534 538 — — —
O2 air pressure (mbar) 213 142 112 113 — — —
O2 saturation (%) 98 T 1 91 T 3
a 78 T 6ab 86 T 4abc 233.66 G0.001 —
No AMS 98 T 1 91 T 3a 79 T 6ab 87 T 4abc 150.93 G0.001 —
AMS 98 T 1 90 T 3a 76 T 5ab 85 T 3abc 95.95 G0.001 0.412
Systolic BP (mm Hg) 118 T 12 127 T 17a 127 T 14a 127 T 14a 4.25 0.006 —
No AMS 120 T 12 128 T 18 127 T 16 127 T 16 2.12 0.101 —
AMS 115 T 13 124 T 16 128 T 10a 128 T 10 3.25 0.030 0.696
Diastolic BP (mm Hg) 75 T 11 86 T 9a 85 T 9a 86 T 8a 16.06 G0.001 —
No AMS 76 T 11 87 T 9a 85 T 10a 85 T 8a 8.74 G0.001 —
AMS 72 T 10 84 T 8a 86 T 7a 87 T 7a 9.00 G0.001 0.354
HR (beatsIminj1) 61 T 12 74 T 13a 84 T 16ab 78 T 15a 15.51 G0.001 —
No AMS 58 T 9 71 T 12a 80 T 15ab 75 T 14a 15.19 G0.001 —
AMS 70 T 16d 79 T 15 91 T 16d 83 T 16 1.88 0.149 0.969
Breathing rate (breathsIminj1) 11 T 2 12 T 2 16 T 4ab 14 T 3abc 22.65 G0.001 —
No AMS 10 T 2 11 T 2 15 T 4ab 13 T 2ab 20.70 G0.001 —
AMS 12 T 3d 13 T 2d 17 T 4ab 16 T 3d 5.32 0.003 0.262
Pulmonary SP (mm Hg) 22 T 3 27 T 4a 35 T 6ab 35 T 6ab 62.24 G0.001 —
No AMS 23 T 3 27 T 4a 35 T 6ab 35 T 7ab 43.02 G0.001 —
AMS 21 T 3 28 T 4a 35 T 5ab 35 T 5ab 18.88 G0.001 0.414
Hematocrit (%) 46 T 4 44 T 5 49 T 6ab 53 T 6abc 30.14 G0.001 —
No AMS 46 T 3 46 T 5 51 T 3ab 55 T 4abc 40.43 G0.001 —
AMS 46 T 5 40 T 4d 46 T 8d 50 T 7bd 4.85 0.004 0.014
Epinephrine (pgImLj1) 56 T 33 42 T 27 35 T 18a 33 T 27a 6.84 G0.001 —
No AMS 54 T 30 46 T 26 38 T 17a 29 T 26a 7.67 G0.001 —
AMS 56 T 26 37 T 30 30 T 17 39 T 29 0.89 0.454 0.039
Norepinephrine (pgImLj1) 361 T 188 583 T 206a 986 T 351ab 823 T 631ab 22.62 G0.001 —
No AMS 374 T 197 553 T 179 976 T 339ab 899 T 643ab 15.33 G0.001 —
AMS 337 T 175 642 T 247 1005 T 382a 680 T 601a 7.06 G0.001 0.315
CT (s) 169 T 20 193 T 14a 204 T 76a 183 T 25 5.49 G0.001 —
No AMS 171 T 24 194 T 15 188 T 64a 187 T 26 5.04 0.003 —
AMS 165 T 11 191 T 11 175 T 41 180 T 24 2.31 0.089 0.928
CFT (s) 76 T 18 91 T 21a 88 T 30a 85 T 27 4.37 0.006 —
No AMS 81 T 18 96 T 22a 95 T 30a 97 T 27 3.72 0.014 —
AMS 65 T 13d 82 T 13d 73 T 25d 75 T 23d 1.79 0.162 0.284
MCF (mm) 61 T 4 60 T 4 62 T 7 66 T 8abc 6.15 G0.001 —
No AMS 60 T 4 59 T 4 61 T 7 64 T 10b 3.65 0.015 —
AMS 63 T 3d 62 T 3d 67 T 6d 68 T 4 3.53 0.022 0.176
> angle (-) 75 T 4 72 T 3a 72 T 8a 73 T 5 4.46 0.004 —
No AMS 74 T 5 71 T 4 70 T 9a 71 T 5 3.83 0.012 —
AMS 77 T 2d 74 T 3d 75 T 5 75 T 4 2.21 0.100 0.257
MAXV (mmIminj1) 18 T 4 14 T 3a 16 T 5a 16 T 4 7.26 G0.001 —
No AMS 17 T 4 14 T 3a 14 T 3a 14 T 3a 7.86 G0.001 —
AMS 20 T 3 15 T 3ad 19 T 5d 18 T 4d 3.30 0.029 0.014
LLS, n 0 1.09 T 1.3a 2.65 T 2.0ab 0.61 T 1.0c 36.13 G0.001 —
0 47 23 7 29 — — —
1–3 0 22 25 16 — — —
4–6 0 2 13 1 — — —
96 0 0 1 0 — — —
Continuous variables are expressed as mean T SD.
a P G 0.05 versus baseline.
b P G 0.05 versus Namche.
c P G 0.05 versus MEBC1.
d P G 0.05 versus AMS at multiple comparison test.
BP, blood pressure; CFT, clot formation time; CT, clotting time; Gr  t, group-by-time interaction; MAXV, maximum velocity; MCF, maximum clot firmness; n, number of subject; SP,
systolic pressure.
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subjects had symptoms of high-altitude sickness with an
LLS 9 0 (AMS in two subjects). When MEBC was reached
(MEBC1), oxygen saturation showed a further reduction,
with an increase in pulmonary artery pressure and respira-
tory rate versus the values measured in Namche (P G 0.05
for all; Table 1). At clinical check (MEBC1), 14 subjects
had AMS (Table 1). After chronic adaptation (MEBC2),
hemoglobin oxygen saturation increased, with significant
reductions of respiratory rate, and only one subject had
AMS (Table 1). Overall, during HIGHCARE expedition, 9
of the 15 women had AMS, whereas 7 of the 32 men had
AMS (P = 0.013 at Fisher exact test between AMS in men
and women).
Acute exposure to hypobaric hypoxia at Namche was
associated with a significant increase of CT and CFT and
reduction of > angle (Table 1). These changes were associ-
ated with a mild but significant increase of plasma norepi-
nephrine (Table 1). At the MEBC1 step, a significant increase
in hematocrit was detectable. At this step, INTEM assay
confirmed the significant reduction of the intrinsic pathway
activity observed at Namche, with norepinephrine plasma
concentration showing a further increase versus Namche
(Table 1).
Predictive modeling. Multivariate modeling through
stepwise linear regression of the data collected from all
participants in the HIGHCARE expedition identified four
parameters independently associated with LLS (Table 2).
In particular, a high velocity of clot formation (MAXV)
increased the likelihood of high LLS (positive independent
association with LLS), whereas oxygen saturation, hemato-
crit, and the duration of trekking at the time of assessment
(days of expedition) decreased the likelihood of high LLS
(negative independent association with LLS; Table 2).
The following algorithm was then created using the
coefficients obtained for each selected variable:
predictive index ¼ 1=½ð0:174 oxygen saturation ð%ÞÞ
þð0:050 hematocrit ð%ÞÞ þ ð0:074 daysÞ
jð0:077MAXVðmmIminj1ÞÞ  100
For example, for a patient who had reached intermediate
altitude with 83% oxygen saturation, 43% hematocrit, on the
first day of expedition, and with a MAXV of 16 mmIminj1,
a predictive index value of 6.48 can be calculated. Values
measured in Namche were then entered into the algorithm
to calculate the predictive index for each participant. Values
ranged between 5 and 7. The predictive index measured in
Namche had a sensitivity of 76.9% and specificity of 76.5%
to predict AMS at MEBC1 for the cutoff value of 5.92
(Fig. 2). ROC analysis was also performed for oxygen sat-
uration, hematocrit, and cutoff values (G91.5%, G43.5%, and
913.5 mmIminj1 respectively; Fig. 2).
Cox proportional-hazards stepwise regression was then
used to analyze the effect of predictive index, hematocrit,
oxygen saturation, and MAXV cutoff values on the occur-
rence of AMS (headache with LLS Q 4 at MEBC1). In
particular, subjects with predictive index Q 5.92 in Namche
had an OR of 5.4 (95% CL = 1.7–17.4, P = 0.004) of
impending AMS.
2010 Monte Rosa research expedition. At the
Gnifetti hut, seven subjects had AMS and were then excluded
from further investigations. A predictive index value G5.92
was measured in 13 subjects; in this group, 10 subjects
TABLE 2. Multivariate modeling of LLS during the HIGHCARE expedition (stepwise
multiple regression analysis).
Selected Variable B Coefficient 95% CL P
O2 saturation (%) j0.174 j0.21 to j0.14 0.000
Hematocrit (%) j0.050 j0.09 to j0.01 0.027
Days (n) j0.074 j0.12 to j0.03 0.002
MAXV (mmIminj1) 0.077 0.02 to 0.14 0.013
Variables included in the model: age, sex, body mass index, day of expedition, atmo-
spheric pressure, CT, CFT, MCF, > angle, MAXV, hematocrit, systolic and diastolic
pressure, HR, respiratory rate, pulmonary artery pressure, oxygen saturation, epineph-
rine and norepinephrine, with LLS as dependent variable.
Multiple r = 0.714.
FIGURE 2—ROC curve of the sensitivity (true positives) versus 1 j specificity (false positives) of the AMS index, hematocrit, oxygen saturation, and
MAXV in Namche Bazaar in predicting AMS (LLS Q 4) 24–48 h after arrival at Mount Everest Base Camp (MEBC1) (left graph). Sensitivity and
specificity of AMS index (right graph).
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remained free from AMS at CM. Conversely, among the 24
subjects with a value of predictive index Q 5.92, 17 had AMS
at CM (P = 0.008 at two-tailed Fisher exact test; sensitivity =
85%, specificity = 59%, positive predictive value = 71%,
negative predictive value = 77%; Table 3). On the other hand,
isolated assessments of oxygen saturation, hematocrit, and
MAXV failed to predict the occurrence of AMS at CM
(Fig. 3). Logistic regression selected the predictive index
as the only predictor of AMS at CM (OR = 8.1, 95% CL =
1.7–38.6, P = 0.009), oxygen saturation, hematocrit, and
MAXV being excluded from the model.
DISCUSSION
The present data reveal the new prospective to combine
different variables measured at intermediate altitude on the
way to the top in a single index able to predict the occur-
rence of AMS at high altitude. Expeditions to high altitude
always consider intermediate steps where collection of
simple data is feasible. In this setting, the addition of point-
of-care instruments can screen mountaineers or local staff
engaged in the expedition who may take advantage of wait-
ing before continuing the trip.
The possible predictive value of oxygen saturation (SaO2)
and of the hypoxic ventilatory response was proposed to
screen individual tolerance to hypoxia, but there is no sci-
entific agreement whether these single tests are really useful
(10). The relationship to AMS susceptibility during the
following expedition steps at high altitude (9,23), observed
when SaO2 was measured after prolonged exposure to
hypoxia at altitude, indicates that the impairment of pul-
monary exchange may occur before the onset of AMS
clinical symptoms (17,28). When the time of exposure to
hypoxia is short, SaO2 changes markedly depend on the
individual hypoxic ventilatory response (9). Studies inves-
tigating the hypoxic ventilator response in a hypobaric
chamber failed, however, to show a consistent associa-
tion with AMS (10). The inclusion in the model of other
factors directly stimulated by hypoxia, such as blood lactate
response, however, increased AMS prediction (10). AMS
symptoms may then ensue as a secondary response, directly
attributed to the reduced SaO2, rather than simply occurring
in conjunction with a declining SaO2 value.
According to the current opinion, AMS is a mild form of
high-altitude cerebral edema, both syndromes sharing a
common pathophysiology linked by vasogenic edematous
brain swelling that ultimately leads to intracranial hyperten-
sion (2,26). The change from aerobic to anaerobic glycoly-
sis, occurring at values of arterial oxygen partial pressure
(1), which can be reached in subjects exposed to high alti-
tude (6,8), seems to play a role in the cytotoxic edema of
subjects with hypoxia-induced AMS (26). The hypoxia-
stimulated systemic accumulation of oxygen free radicals (2)
may also have important implications for the vascular sys-
tem by enhancing tissue factor at the transcriptional, as well
as at the functional level, in endothelial cells (15). Previous
studies performed at altitude revealed a mild activation of
the intrinsic pathway of blood coagulation with a significant
shortening of activated partial thromboplastin time linked to
the increase of factor VIII procoagulant activity and von
Willebrand factor antigen, in individuals with AMS (3,4). In
addition to oxygen saturation, hematocrit value, and day of
expedition, indeed multivariate analysis performed on our
data selected the predictive value of the velocity of clot
formation (MAXV) on activation of the intrinsic pathway.
The acute exposure to hypobaric hypoxia at Namche,
which was reached very quickly because of the helicopter
flight from Katmandu, was characterized by a longer time of
TABLE 3. Characteristics of subjects with predictive index values at the Gnifetti hut G5.92 or Q5.92 and clinical assessment at 24 and 48 h after arrival at CM.
Index G 5.92 Index Q 5.92
Location Variables n = 13 n = 24 P
Gnifetti hut O2 saturation (%) 90.3 T 1.6 87.2 T 3.2 0.002
Hematocrit (%) 51.1 T 8.4 43.7 T 6.0 0.004
MAXV (mmIminj1) 14.3 T 5.2 17.7 T 4.5 0.045
Predictive AMS index 5.8 T 0.1 6.3 T 0.3 —
CM LLS, n 24 h 48 h 24 h 48 h
0 2 3 1 1
1–3 9 8 8 14
4–6 2 2 9 5
96 0 0 6 3
AMS+ 7 17 0.008a
AMSj 10 3
Continuous variables are expressed as mean T SD.
a Two-tailed Fisher exact probability test.
AMS, acute mountain sickness (headache and LLS Q 4).
FIGURE 3—Univariate OR of developing AMS within 24–48 h after
arrival at the CM hut (4559 m) for subjects with AMS index Q6, oxygen
saturation G91.5%, MAXV 913.5 mmIminj1, and hematocrit G43.5%
after an overnight stay at the Gnifetti hut (3647 m).
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clot formation (CT), a reduced velocity of clot formation
(MAXV), and a significantly reduced > angle. Interestingly,
the same depression of the intrinsic pathway of coagulation
was still evident on arrival at MEBC1. At a further explo-
ration of global data, multivariate stepwise analysis, how-
ever, selected a marker of coagulation activity (MAXV) as a
positive independent predictor of LLS. The use of a simple
point-of-care test such as thromboelastometry within the
frame of a Himalayan expedition allowed us to overcome all
logistic difficulties in performing a large battery of single
coagulation tests. The correct transportation of blood sam-
ples to the central laboratory, a crucial point for all coagu-
lation assays, might indeed represent an important source of
bias in studies performed in the Himalayan region.
Altitudes ranging between 2300 and 4200 m were reported
to be especially adequate for the determination of AMS
susceptibility (9). Therefore, values measured in Namche
(3400 m) of the four parameters selected as independent
predictors of AMS (oxygen saturation, hematocrit, day of
expedition, and MAXV) were used to build a predictive
index for predicting AMS at MEBC (5400 m). Namche was
reached by helicopter; thus, the possible confounding role of
exercise was limited (24).
During the investigation in the Italian Alps, the predictive
index test correctly identified individuals at risk for AMS
in 85% of cases (sensitivity). The remaining 15% of people
tested did not show the expected result for this test. For that
15%, the finding of a ‘‘normal’’ result can be misleading
(false negative). A test’s sensitivity is particularly important
when searching to exclude a dangerous disease. In the pres-
ent case, we decided to set the limit to a moderate value of
LLS rather than attempt to screen more advanced stages of
AMS. It might be difficult to make the subject understand
and accept the possibility of having to wait before continu-
ing the trip in the absence of AMS. However, it would be
advisable to provide correct information of the possible
onset of AMS in that single mountaineer, either for the
subject itself or for the head of the expedition. On the other
hand, the ability of the test to correctly exclude individ-
uals who would not develop AMS (specificity) was 59%.
Although unwarranted anxiety may be caused by the test
in 41% of the subjects, the consequences of false positives
are still minor at high altitude.
Cutoff values and predictive utility of SaO2 measured
at intermediate altitude 94200 m were indeed reported in
studies with prospective field design (16,23). However, only
information on negative predictive value (91%) is available
for SaO2 measured at 3500 m (16). Likewise, SaO2 mea-
sured at the Gnifetti hut (3647 m) failed to predict impend-
ing AMS (Fig. 3). The integration of clinical and laboratory
parameters in a single predictive index seems to be an ad-
vancement to investigate the complexity of AMS, although
blood withdrawal may represent a main disadvantage of the
strategy.
In conclusion, the present study explores for the first time
the possibility to include different parameters, measured at
intermediate altitude, in predictive index, to predict the onset
of AMS at high altitude. The prospective study performed
with this approach supports the possibility to screen recrea-
tional climbers who may gain advantage from waiting
before continuing the trip, combining results from different
point of care instruments. We propose that sensitivity (85%)
and specificity (59%) of the predictive AMS index should
stimulate further improvement by future studies, which
might usefully explore a different combination of point of
care tests, aimed at refining an optimal screening procedure
that might be proposed for general implementation in huts
at intermediate altitude, to reduce the risk of health problems
in subjects on their way to high altitude targets.
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